Role of liver fibrosis using indirect serological markers in prediction of non-responders and relapsers to sofosbuvir-based treatment in patients with HCV infection

Abstract

HCV infection is one of the main causes of chronic liver disease worldwide. In Egypt, which has the highest prevalence of chronic HCV, the treatment poses an economic burden on the government (El-Zanaty and Way 2008). Ogawa et al. (2015) study showed that non-invasive fibrosis assessments (FibroScan, APRI, FIB-4) are valuable in predicting SVR by prior partial or null responders in telaprevir-based triple therapy. So this study aimed at assessing role of liver fibrosis using APRI, FIB4, and GUCI -as predictors of liver fibrosis- to assess the virological response to Sofosbuvir-based regimen therapy in Egyptian patients with chronic HCV infection. This study enrolled (80) patients with chronic HCV infection who received anti-viral treatment as part of the national program for combating viral hepatitis in Egypt. They were divided into group (1) and (2). Group (1) included (50) patients who maintained a virological level undetectable by PCR at week 16 and week 24 from treatment start (cured).